Vanishing White Matter Disease
Conditions
Keywords
Neurodegenerative Diseases, Nervous System Diseases, Central Nervous System Brain Diseases, Hereditary Central Nervous System, Leukoencephalopathy with Vanishing White Matter
Brief summary
Fosigotifator is an investigational drug being researched for the treatment of Vanishing White Matter disease in adult, pediatric and infant participants. This is a 201-week, open-label, multiple cohort study enrolling adults, pediatric and infant participants with Vanishing White Matter disease. Participants will attend regular visits during the course of the study and complete medical assessments, blood tests, questionnaires, and be evaluated for side effects.
Interventions
DRUGFosigotifator
Oral Use
Sponsors
Calico Life Sciences LLC
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
6 Months to No maximum
Healthy volunteers
No
Inclusion criteria
1. Males and females \>= 6 months of age at the time of Screening. 2. Have VWM disease defined as: 1. A clinical diagnosis by a physician experienced in the assessment of VWM disease; and 2. A molecular diagnosis of VWM disease, and 3. A magnetic resonance imaging (MRI) presentation consistent with VWM disease. 3. Have a designated caregiver who is able to complete the respective caregiver-centered assessments. 4. Signed and dated informed consent provided by the participant, or from a legally authorized representative (LAR) if participant is incapable to consent themselves. 5. Participants must meet criteria (a) and at least one of the following functional criteria (b or c): 1. Medical history of at least 1 neurological symptom that is assessed by the investigator as having a reasonable possibility of being related to VWM disease. 2. Motor criteria defined as inability to walk 10 or more steps with or without light support of 2 hands 3. Cognitive criteria as assessed by the age-appropriate version of the Wechsler Intelligence Scale, with participants scoring \< 50 on specific indices; specific details can be provided by the Study physician. 6. Pediatric participants in Cohort 4 must meet both criteria a and b below, or criterion c: 1. Medical history of at least 1 neurological symptom that is assessed by the investigator as having a reasonable possibility of being related to VWM disease. 2. Motor criteria as defined below: i. More than minimal head control as demonstrated by: While in prone position, the participant can lift his/her head and sustain the position for 10 seconds and bring his/her arms actively to weight bearing in that position. c. Presymptomatic and homozygous for Cree Leukoencephalopathy (EIF2B5 R195H) or other mutation with known imminent risk of significant clinical decline or death (sponsor must be notified and provide approval prior to screening and enrolling a participant that meets eligibility with only this criterion). 7. All male participants who are sexually active and not surgically sterilized must agree to use an acceptable contraceptive method. Additionally, male participants must agree to not donate sperm during the study until 30 days after the final dose of study drug. 8. All female participants who are sexually active and of childbearing potential must agree to use a highly effective contraceptive method. Additionally, female participants must agree to not donate eggs during the study and for 30 days after the final dose of study drug.
Exclusion criteria
1. Pediatric participants \>= 6 months and \< 6 years of age must not be on any form of respiratory support at the time of Screening. 2. Changes in medication use for the management of VWM disease symptoms within the 4 weeks preceding Screening. 3. Seizure disorder not considered adequately controlled by the investigator within the 6 months preceding Screening. 4. Participant who, in the opinion of the investigator, is incapable of completing study-required visits and procedures to assess primary and secondary endpoints. 5. Adult female participants who are pregnant, breastfeeding or providing breast milk. 6. Treatment with any other investigational treatment within 30 days or 5 half-lives (whichever is longer) prior to Baseline. 7. Any clinically significant laboratory or imaging findings at Screening.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of Treatment-Emergent Adverse Events | Baseline up to Approximately Day 28 | Number of participants with treatment-related adverse events as assessed by CTCAE v4.03 |
| Number of Participants with Change in Vital Signs | Baseline up to Approximately Day 28 | Number of Participants with Change in Vital Signs will be assessed. |
| Number of Participants with Change in ECG | Baseline up to Approximately Day 28 | Number of Participants with Change in ECG will be assessed. |
| Number of Participants with Change in Clinical Laboratory Tests | Baseline up to Approximately Day 28 | Number of participants with change in clinical laboratory tests will be assessed. |
| Change from Baseline in Columbia-Suicide Severity Rating Scale (C-SSRS) | Baseline up to Approximately Day 28 | The C-SSRS is a systematically administered instrument that reports the severity of both suicidal ideation and behavior, with a higher score denoting more severe suicidal ideation and behavior. |
| Plasma Concentration of Fosigotifator | Baseline up to approximately Week 96 | Maximum Plasma Concentration \[Cmax\] |
| Time to Cmax (Tmax) of Fosigotifator | Baseline up to approximately Week 96 | Tmax of Fosigotifator |
| Area Under the Plasma Concentration-Time Curve (AUC0-24h) of Fosigotifator | Baseline up to approximately Week 96 | AUC0-24h of Fosigotifator |
| Trough Concentration (Ctrough) of Fosigotifator | Baseline up to approximately Week 96 | Ctrough of Fosigotifator |
| Terminal Elimination Half-Life (t1/2) of Fosigotifator | Baseline up to approximately Week 96 | t1/2 of Fosigotifator |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of Treatment-Emergent Adverse Events | Baseline up to Approximately Week 197 | Number of patients with treatment-related adverse events as assessed by CTCAE v4.03 |
| Number of Participants with Change in Vital Signs | Baseline up to approximately Week 197 | Number of Participants with Change in Vital Signs will be assessed. |
| Number of Participants with Change in ECG | Baseline up to approximately Week 197 | Number of Participants with Change in ECG will be assessed. |
| Number of Participants with Change in Clinical Laboratory Tests | Baseline up to approximately Week 197 | Number of participants with change in clinical laboratory tests will be assessed. |
| Change from Baseline in Columbia-Suicide Severity Rating Scale (C-SSRS) | Baseline up to approximately Week 197 | The C-SSRS is a systematically administered instrument that reports the severity of both suicidal ideation and behavior, with a higher score denoting more severe suicidal ideation and behavior. |
| Number of Participants with Change in Magnetic Resonance Imaging (MRI) | Baseline up to approximately Week 192 | Change in Brain Magnetic Resonance Imaging (MRI) associated with adverse events. |
Countries
Canada, Netherlands, United States
Contacts
CONTACTCall Center - English
Outcome results
None listed